MX2020012532A - Composiciones y procedimientos de su uso para el tratamiento de esclerosis lateral amiotrofica (ela). - Google Patents
Composiciones y procedimientos de su uso para el tratamiento de esclerosis lateral amiotrofica (ela).Info
- Publication number
- MX2020012532A MX2020012532A MX2020012532A MX2020012532A MX2020012532A MX 2020012532 A MX2020012532 A MX 2020012532A MX 2020012532 A MX2020012532 A MX 2020012532A MX 2020012532 A MX2020012532 A MX 2020012532A MX 2020012532 A MX2020012532 A MX 2020012532A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- als
- methods
- same
- lateral sclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se proporcionan composiciones y procedimientos de su uso para el tratamiento de esclerosis lateral amiotrófica (ELA). En consecuencia, se proporciona un procedimiento para el tratamiento de ELA en un paciente humano que lo necesita, comprendiendo el procedimiento la administración intravenosa (IV) al paciente de 2 - 5 mg/kg de un péptido que comprende una secuencia de aminoácidos, tal como se establece en la SEQ ID NO: 1. Se proporciona también composiciones y formas de dosificación unitaria que comprenden un péptido que comprende una secuencia de aminoácidos tal como se establece en la SEQ ID NO: 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862678316P | 2018-05-31 | 2018-05-31 | |
| PCT/IL2019/050619 WO2019229757A1 (en) | 2018-05-31 | 2019-05-30 | Compositions and methods of using same for treating amyotrophic lateral sclerosis (als) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020012532A true MX2020012532A (es) | 2021-04-28 |
Family
ID=68697171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020012532A MX2020012532A (es) | 2018-05-31 | 2019-05-30 | Composiciones y procedimientos de su uso para el tratamiento de esclerosis lateral amiotrofica (ela). |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210100869A1 (es) |
| EP (1) | EP3785279A4 (es) |
| JP (1) | JP7350019B2 (es) |
| AU (1) | AU2019277920A1 (es) |
| CA (1) | CA3099846A1 (es) |
| IL (1) | IL279108B2 (es) |
| MX (1) | MX2020012532A (es) |
| WO (1) | WO2019229757A1 (es) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001072326A1 (en) * | 2000-03-31 | 2001-10-04 | Smithkline Beecham Plc | Use of crf receptor agonists for the treatment or prophylaxis of diseases, for example neurodegenerative diseases |
| US20030140362A1 (en) * | 2001-06-08 | 2003-07-24 | Dennis Macejak | In vivo models for screening inhibitors of hepatitis B virus |
| CN101035554A (zh) * | 2004-08-23 | 2007-09-12 | 维兹曼科学研究所耶达研究与发展有限公司 | 介导应激反应的肽抑制剂 |
| RU2007115543A (ru) * | 2004-10-28 | 2008-12-10 | Уорнер-Ламберт Компани Эл-Эл-Си (US) | Способ получения аморфного аторвастатина |
| DK2086331T3 (da) * | 2006-11-10 | 2013-05-27 | Genervon Biopharmaceuticals Llc | Fremgangsmåder til behandling af neuronale lidelser ved anvendelse af MNTF-peptider og analoger deraf. |
| CN101677948A (zh) * | 2007-06-07 | 2010-03-24 | 纳斯泰克制药公司 | 卡贝缩宫素鼻用制剂和治疗孤独症的方法 |
| EP3263127B1 (en) * | 2011-05-23 | 2019-08-21 | Yeda Research and Development Co. Ltd | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
| EP3191096A4 (en) * | 2014-09-12 | 2018-03-21 | Lixte Biotechnology, Inc. | Human dosing of phosphatase inhibitor |
| AU2015346162B2 (en) * | 2014-11-14 | 2022-02-10 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
-
2019
- 2019-05-30 MX MX2020012532A patent/MX2020012532A/es unknown
- 2019-05-30 AU AU2019277920A patent/AU2019277920A1/en active Pending
- 2019-05-30 CA CA3099846A patent/CA3099846A1/en active Pending
- 2019-05-30 WO PCT/IL2019/050619 patent/WO2019229757A1/en active Application Filing
- 2019-05-30 IL IL279108A patent/IL279108B2/en unknown
- 2019-05-30 JP JP2020565903A patent/JP7350019B2/ja active Active
- 2019-05-30 EP EP19811026.4A patent/EP3785279A4/en active Pending
-
2020
- 2020-11-26 US US17/105,557 patent/US20210100869A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210100869A1 (en) | 2021-04-08 |
| EP3785279A4 (en) | 2022-07-27 |
| JP7350019B2 (ja) | 2023-09-25 |
| IL279108A (en) | 2021-01-31 |
| EP3785279A1 (en) | 2021-03-03 |
| JP2021524858A (ja) | 2021-09-16 |
| AU2019277920A1 (en) | 2021-01-07 |
| CA3099846A1 (en) | 2019-12-05 |
| IL279108B1 (en) | 2024-06-01 |
| IL279108B2 (en) | 2024-10-01 |
| WO2019229757A1 (en) | 2019-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA521430398B1 (ar) | Ph20 تركيبة صيدلانية، تشمل متغير ودواء هيالورونيداز البشرى، للحقن تحت الجلد | |
| MX2020004969A (es) | Composiciones y procedimientos para tratar cancer. | |
| WO2018067217A3 (en) | COMPOSITIONS COMPRISING SHORT PEPTIDES DERIVED FROM PEDF AND USES THEREOF | |
| NZ763572A (en) | Trispecific proteins and methods of use | |
| NZ628126A (en) | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases | |
| MX2012008999A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012008998A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012009000A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| NZ603028A (en) | Tfpi inhibitors and methods of use | |
| MX2017006372A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular. | |
| NZ602693A (en) | Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae | |
| WO2012012600A3 (en) | Peptide compounds for regulating the complement system | |
| MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| EP4349360A3 (en) | Peptide exhibiting wrinkle-improving activity and uses thereof | |
| MX2021014497A (es) | Peptidos. | |
| PH12021551232A1 (en) | Haloallylamine compounds and application thereof | |
| MX2021003109A (es) | Proteina para el tratamiento de enfermedades inflamatorias. | |
| NZ703514A (en) | Fviii peptides for immune tolerance induction and immunodiagnostics | |
| MX2019005466A (es) | Composiciones y metodos para tratar diabetes, hipertension e hipercolesterolemia. | |
| NZ756128A (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| MX2015007402A (es) | Fusion de hormona de crecimiento humano y albumina, formulacion y usos de los mismos. | |
| MX2017002476A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular. | |
| FI3998067T3 (fi) | Koostumukset ja menetelmät homokystinurian hoitoon | |
| MY193963A (en) | Composition for treating joint diseases and kit containing same |